日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway.

NMOSD 和复发性 MOGAD 中耐受因子 sCD83 降低:一种潜在的新治疗途径

Rechtman Ariel, Zveik Omri, Shweiki Lyne, Hoichman Garrick, Friedman-Korn Tal, Brill Livnat, Vaknin-Dembinsky Adi

Subclinical imaging activity in multiple sclerosis patients during war-related psychological stress

战争相关心理压力下多发性硬化症患者的亚临床影像学活动

Zveik, Omri; Friedman-Korn, Tal; Rechtman, Ariel; Ganz, Tal; Hoichman, Garrick; Shweiki, Lyne; Ekstein, Dana; Vaknin-Dembinsky, Adi

Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkers

NMOSD 和 MOGAD 中的脑萎缩:体积和 DTI 生物标志物的荟萃分析

Rechtman, Ariel; Zveik, Omri; Vaknin-Dembinsky, Adi

The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells

炎症与髓鞘再生之间的相互作用:以少突胶质细胞祖细胞为重点重新思考多发性硬化症的治疗

Zveik, Omri; Rechtman, Ariel; Ganz, Tal; Vaknin-Dembinsky, Adi

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

评估2023年国际MOGAD专家组标准在真实临床环境中的适用性

Rechtman, Ariel; Freidman-Korn, Tal; Zveik, Omri; Shweiki, Lyne; Hoichman, Garrick; Vaknin-Dembinsky, Adi

Correction to: Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

更正:评估 2023 年国际 MOGAD 专家组标准在真实临床环境中的适用性

Rechtman, Ariel; Friedman-Korn, Tal; Zveik, Omri; Shweiki, Lyne; Hoichman, Garrick; Vaknin-Dembinsky, Adi

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

严重急性呼吸综合征冠状病毒2型第三剂疫苗在接受奥克瑞珠单抗治疗的多发性硬化症患者中的免疫反应

Brill, Livnat; Raposo, Catarina; Rechtman, Ariel; Zveik, Omri; Levin, Netta; Oiknine-Djian, Esther; Wolf, Dana G; Vaknin-Dembinsky, Adi

Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells

进行性多发性硬化症患者的脑脊液会降低少突胶质细胞祖细胞的分化和免疫功能。

Omri Zveik ,Nina Fainstein ,Ariel Rechtman ,Nitzan Haham ,Tal Ganz ,Iris Lavon ,Livnat Brill ,Adi Vaknin-Dembinsky

Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine

在接受第二剂和第三剂SARS-CoV-2 mRNA疫苗后,使用克拉屈滨片剂治疗的多发性硬化症患者的纵向体液免疫反应

Brill, Livnat; Rechtman, Ariel; Shifrin, Alla; Rozenberg, Ayal; Afanasiev, Svetlana; Zveik, Omri; Haham, Nitzan; Levin, Neta; Vaknin-Dembinsky, Adi

Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis

克拉屈滨对多发性硬化症患者接种两剂BNT162b2 mRNA疫苗后COVID-19血清学反应的影响

Brill, Livnat; Rechtman, Ariel; Zveik, Omri; Haham, Nitzan; Levin, Netta; Shifrin, Alla; Rozenberg, Ayal; Vaknin-Dembinsky, Adi